Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBIT (2016 - 2025)

Historic EBIT for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$56.9 million.

  • Spyre Therapeutics' EBIT fell 270.08% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 1056.58%. This contributed to the annual value of -$208.6 million for FY2024, which is 1392.35% up from last year.
  • Latest data reveals that Spyre Therapeutics reported EBIT of -$56.9 million as of Q3 2025, which was down 270.08% from -$41.9 million recorded in Q2 2025.
  • Spyre Therapeutics' EBIT's 5-year high stood at -$6.7 million during Q2 2021, with a 5-year trough of -$159.2 million in Q2 2023.
  • Over the past 5 years, Spyre Therapeutics' median EBIT value was -$24.4 million (recorded in 2022), while the average stood at -$39.7 million.
  • Per our database at Business Quant, Spyre Therapeutics' EBIT crashed by 61019.04% in 2023 and then skyrocketed by 7227.75% in 2024.
  • Spyre Therapeutics' EBIT (Quarter) stood at -$20.4 million in 2021, then grew by 6.26% to -$19.2 million in 2022, then crashed by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then grew by 7.13% to -$56.9 million in 2025.
  • Its EBIT stands at -$56.9 million for Q3 2025, versus -$41.9 million for Q2 2025 and -$53.6 million for Q1 2025.